About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are exploring the hidden depths of cancer and T-cell biology to discover and characterize unconventional immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from the altered cellular processes in cancer cells.

Enara Bio is backed by leading life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with a number of world class academic institutions including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive our differentiated science.

Enara Bio Our Story Poster

The Team

Andrew Fadden
Vice President, Corporate Development
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer
Erik Rutjens
Vice President, Cell Therapy Operations
Joseph Dukes
Vice President, Head of Research
Lucy Gallacher (Research Associate), Daniella Colbourne (Technician), Tatiana Lobry (Scientist), Nathifa Moyo (Senior Scientist), Angharad Lloyd (Associate Director, Immunology),
David Watson (Chief Operating Officer), Andrew Fadden (Vice President, Corporate Development), Kevin Pojasek (President and Chief Executive Officer), Joe Dukes (Vice President, Head of Research), Sophie Papa (Chief Medical Officer), Erik Rutjens (Vice President, Cell Therapy Operations)
Charlotte Howard (Associate Director, Corporate and Executive Administration)
Colin Moore (Senior Scientist), Charlotte Chapman (Senior Scientist), Mengqiu Li (Senior Scientist)
Kate Fynes (Cell Process Development Lead, Principal Scientist), Assa Oumie (Principal Scientist), Selsabil Dhaouadi (Scientist)
Jo Senra (Associate Director, Preclinical Validation), Veronica Freire-Beneitez (Senior Scientist), Vicki Jefferson (Scientist)
Rachel Abbott (Head of TCR Pipeline and Dark Antigen Research)
Emily Lam (Senior Scientist), Duncan Howie (Director of Immunology), Suzanne Cole (Principal Scientist),
Luke Williams (Senior Director, Biology)
Beth Turner (Head of Product and Pipeline Project Management), Simon Jarvis (IT Director), Kate Nicholson (Head of Business Operations), Jonathon Dines (Finance Director), Ray Duffy (Associate Director, Facilities and EHS)
Ron Wolchinsky (Associate Director, Molecular Immunology), Giulia Masi (Principal Scientist)
Adam Taylor (Senior Director, Business Insights and Strategy), Andrew Fadden (Vice President, Corporate Development), Jonathan Porter (Director, Intellectual Property), Hayden Selvadurai (Director, Corporate Development)
Stephane Lameynardie (Director, Cell Therapy Operations and Supply Chain)
Duncan Howie (Director, Immunology)
Rayner Queiroz (Senior Scientist), Fabio Marino (Associate Director, Immunopeptidomics), Rose Gathungu (Principal Scientist)
Jon Silk (Director, MR1 Research), Duncan Howie (Director, Immunology), Joe Dukes (Vice President, Head of Research), Rachel Abbott (Head of TCR Pipeline and Dark Antigen Research), Luke Williams (Senior Director, Biology),
Sophie Papa (Chief Medical Officer), Joseph Dukes (Vice President, Head of Research)
Jon Silk (Director, MR1 Research)
Eleanor Denham (Scientist), Phyllis Tea (Research Associate)
Ron Wolchinsky (Associate Director, Molecular Immunology)
Prathiba Kurupati (Senior Scientist), Jo Senra (Associate Director, Preclinical Validation), Veronica Freire-Beneitez (Senior Scientist), Vicki Jefferson (Scientist), Emily Tye (Research Associate)
Adam Taylor (Senior Director, Business Insights and Strategy), Andrew Fadden (Vice President, Corporate Development)
Stephane Lameynardie (Director, Cell Therapy Operations and Supply Chain), Erik Rutjens (Vice President, Cell Therapy Operations)
Emily Lam (Senior Scientist), Suzanne Cole (Principal Scientist), Phyllis Tea (Research Associate), Terri Cornforth (Principal Scientist), Eleanor Denham (Scientist), Duncan Howie (Director of Immunology)

Board of Directors

Scientific Advisory Board

Andrew Fadden

Vice President, Corporate Development

Andrew joined Enara Bio in 2019 and brings over 12 years of drug development, corporate development and leadership experience in the biotech and pharmaceutical industry.

Previously, Andrew was a Director in the Program Leadership Group at Immunocore, where he led multiple early-phase programs from discovery research into clinical development. He was also a key part of the team that agreed a clinical-stage, co-development partnership with Genentech. Prior to Immunocore, Andrew was the Global Regulatory Affairs Lead for the Oncology Portfolio at Vertex Pharmaceuticals, and held positions of increasing responsibility in Global Regulatory Affairs and Global Development Teams at UCB and GlaxoSmithKline.

Andrew received an MA in Molecular and Cellular Biochemistry at the University of Oxford and he has a PhD from University College London following research at Cancer Research UK’s London Research Institute. Andrew also holds an Executive MBA (with Distinction) from Warwick Business School.